Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Alto Neuroscience's operating assets for the quarter that ended in Mar. 2026 was $12.50 Mil. Alto Neuroscience's operating liabilities for the quarter that ended in Mar. 2026 was $9.68 Mil. Alto Neuroscience's Total Assets for the quarter that ended in Dec. 2025 was $184.69 Mil. Therefore, Alto Neuroscience's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.02.
Alto Neuroscience Scaled Net Operating Assets Related Terms
Alto Neuroscience Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Alto Neuroscience's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alto Neuroscience Scaled Net Operating Assets Chart
ANRO vs MRVI, BBOT, REPL: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, Alto Neuroscience's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alto Neuroscience Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alto Neuroscience's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Alto Neuroscience's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.02 mean?
Alto Neuroscience (ANRO) has a Scaled Net Operating Assets of 0.02 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Alto Neuroscience and its competitors.
Is Alto Neuroscience's Scaled Net Operating Assets too high?
Alto Neuroscience's current Scaled Net Operating Assets is 0.02. Overall, Alto Neuroscience has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alto Neuroscience's Scaled Net Operating Assets compare to MRVI and BBOT?
Alto Neuroscience's Scaled Net Operating Assets of 0.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Alto Neuroscience and its competitors. Alto Neuroscience's current Scaled Net Operating Assets is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alto Neuroscience stock overvalued right now?
Alto Neuroscience (ANRO) has a current Scaled Net Operating Assets of 0.02. The current Scaled Net Operating Assets is 0.02. Alto Neuroscience's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Alto Neuroscience (ANRO), the current Scaled Net Operating Assets is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
12GF Score
Get the complete analysis for ANRO
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANRO has been successfully added to your 
